ConductScience.org, home

Paper · 42258481

Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.

Wu X and 4 others. CA Cancer J Clin, 2026. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates. Papers, record 42258481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42258481

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.
PubMed
Journal
CA Cancer J Clin
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-10-11
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics2

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunoglobulin Light-chain AmyloidosisMajor topic
Humans

Source PubMed

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMedNIH RePORTER
R01 CA279808NCI NIH HHSUnited StatesR01CA279808PubMedNIH RePORTER
R01-CA279808Division of Cancer Prevention, National Cancer InstituteR01CA279808PubMedNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References154

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
141,082,956Comparative Outcomes and Cardiac Imaging Features in Light Chain Versus Transthyretin Cardiac Amyloidosis: A Multicenter Retrospective Cohort Study.Am J Cardiol2025https://conductscience.org/library/papers/41082956PubMed
234,521,113Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis.Blood2021https://conductscience.org/library/papers/34521113PubMed
331,606,365A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.JACC Heart Fail2019https://conductscience.org/library/papers/31606365PubMed
432,027,745Organ responses with daratumumab therapy in previously treated AL amyloidosis.Blood Adv2020https://conductscience.org/library/papers/32027745PubMed
524,412,186CMR-based differentiation of AL and ATTR cardiac amyloidosis.JACC Cardiovasc Imaging2014https://conductscience.org/library/papers/24412186PubMed
639,350,582Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee.Amyloid2024https://conductscience.org/library/papers/39350582PubMed
740,788,174Impact of autonomic dysfunction in light chain amyloidosis patient with nephrotic syndrome and cardiac involvement.Amyloid2025https://conductscience.org/library/papers/40788174PubMed
829,437,606Opening a can of worms in AL progression.Blood2018https://conductscience.org/library/papers/29437606PubMed
928,370,245Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.Am J Hematol2017https://conductscience.org/library/papers/28370245PubMed
1033,170,349Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study.Clin Res Cardiol2021https://conductscience.org/library/papers/33170349PubMed

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

None in this release.

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42258481

GET https://conductscience.org/api/papers/v1/42258481/references?page=2